InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares InMed Pharmaceuticals and CorMedix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InMed Pharmaceuticals | $4.94 million | 0.93 | -$12.56 million | ($1.64) | -0.85 |
| CorMedix | $457.20 million | 1.37 | $163.05 million | $2.14 | 3.77 |
CorMedix has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares InMed Pharmaceuticals and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InMed Pharmaceuticals | N/A | -156.08% | -123.90% |
| CorMedix | 40.49% | 40.52% | 20.61% |
Volatility and Risk
InMed Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for InMed Pharmaceuticals and CorMedix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InMed Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| CorMedix | 0 | 2 | 7 | 0 | 2.78 |
CorMedix has a consensus price target of $15.00, suggesting a potential upside of 85.99%. Given CorMedix’s stronger consensus rating and higher probable upside, analysts plainly believe CorMedix is more favorable than InMed Pharmaceuticals.
Summary
CorMedix beats InMed Pharmaceuticals on 14 of the 14 factors compared between the two stocks.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
